Calidi Biotherapeutics Presents New Data on CLD-401 at SITC Annual Meeting.

Calidi Biotherapeutics presented new data on its first therapeutic candidate, CLD-401, at the Society of Immunotherapy for Cancer Annual Meeting. CLD-401 is a tumor-tropic oncolytic virus designed to target metastatic sites, replicate only in tumor cells, induce immune priming, and express high levels of IL-15 superagonist, a potent cytokine. The data showed that the RedTail platform is protected from immune clearance and can specifically replicate in tumor cells at metastatic sites.